Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.56M P/E - EPS this Y -1.80% Ern Qtrly Grth -
Income -11.57M Forward P/E -2.88 EPS next Y -80.40% 50D Avg Chg -8.00%
Sales 477k PEG - EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 8.03 EPS next 5Y - 52W High Chg -25.00%
Recommedations 2.50 Quick Ratio 0.32 Shares Outstanding 26.87M 52W Low Chg 78.00%
Insider Own 33.84% ROA -113.89% Shares Float 17.59M Beta 1.49
Inst Own 7.71% ROE -703.62% Shares Shorted/Prior 535.91K/98.28K Price 1.96
Gross Margin - Profit Margin - Avg. Volume 25,955 Target Price -
Oper. Margin -16,030.77% Earnings Date May 8 Volume 11,925 Change -2.49%
About BioCardia, Inc.

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BioCardia, Inc. News
04/02/24 Insiders Are Buying These 11 Penny Stocks
04/01/24 BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
03/29/24 BioCardia Full Year 2023 Earnings: Misses Expectations
03/28/24 Q4 2023 BioCardia Inc Earnings Call
03/27/24 BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
03/20/24 BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
03/13/24 BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
03/12/24 BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
03/04/24 BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
02/08/24 BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
01/31/24 BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
01/03/24 BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
01/01/24 Positive Signs As Multiple Insiders Buy BioCardia Stock
12/19/23 BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
12/18/23 BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
11/29/23 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval
11/16/23 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
11/15/23 BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
11/14/23 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure
11/09/23 BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript
BCDA Chatroom

User Image Sergioski Posted - 7 hours ago

$BCDA Cellprothera enrolled their final patient in phase I/IIb Protheracytes trial in October of 2023...the 6 month data will be available in April and readout should occur in May. Biocardia writes in the below article that conditional approval could be granted if this readout is successful, this would allow for limited marketing while they undergo phase III. If this is the case, BCDA's helix catheter could be commercially available in Europe as soon as this year https://www.biocardia.com/investors/press-releases/id/1037?pressReleaseId=151

User Image InvestForDaKids Posted - 1 day ago

$BCDA https://www.cbsnews.com/amp/news/fda-announces-recall-heart-pumps-heartmate-deaths-injuries/

User Image Jesus2312 Posted - 2 days ago

$ADIL this stock is moving so good this days, waiting for $BCDA $SINT do the same

User Image Jusme Posted - 5 days ago

$BCDA Looks like AbortedatBirth was booted and his Trash posts deleted… he’ll simply resurrect in a newID like a stubborn wart.

User Image Doorkey Posted - 5 days ago

$AGEN Still better than $BCDA

User Image Jusme Posted - 1 week ago

$BCDA Shorts 💩 jumping off their ledge of insanity 👇

User Image Market_Luther_King Posted - 1 week ago

$BCDA looks like she's holding up well today

User Image RollingDollar Posted - 1 week ago

$BCDA

User Image nbstocks85 Posted - 1 week ago

$BCDA

User Image Sergioski Posted - 1 week ago

Aborted at Birth, the whole market is red and yet $BCDA is green, better cover before you get torched

User Image Jusme Posted - 1 week ago

$BCDA It takes a village… to have a village i.d.i.o.t! 👇

User Image Market_Luther_King Posted - 1 week ago

$BCDA @Jusme @Aborted_at_Birth every board he posts in, he's short. And he spams them heavily. He's paid by a large org to do this crap because no regular human does this to a stock like this. They'd be doing it to Boeing where there were obvious issues where shorting makes sense. Who really bashes a ~$10 million market cap biotech with amazing treatment and tech that'll benefit millions? Someone with a stake in a competitor that realizes Biocardia has something solid and they're afraid.

User Image Jusme Posted - 1 week ago

$BCDA Warning ⚠️ @Aborted_at_Birth 👇 is going to be forced to cover! He’s very desperate.

User Image Market_Luther_King Posted - 1 week ago

$BCDA I'm wondering if Frost reduced his ownership to 4.8% so he wouldn't have to report anymore? 🤔

User Image Jusme Posted - 1 week ago

$BCDA Reflecting on the company’s Annual Meeting agenda which includes a RS provision, this is a stopgap measure to address compliance requirement if they lose an appeal - necessitating a RS following Nasdaq decision - to be actioned by June, or don’t meet requirements by end of 180 day extension period - which would put RS into late Q3 - Q4. At a $10M mkt cap the company is trading at a huge discount to the IP and pipeline value.

User Image Win00799 Posted - 1 week ago

$BCDA The company is looking into a potential reverse split at their next meeting. That is not what I was hoping for.

User Image Sergioski Posted - 1 week ago

$BCDA Looking to continue to add at bargain prices, the market has this one wrong...

User Image Jesus2312 Posted - 1 week ago

$TARA it was fun this last month but and closing this and adding $BCDA and $SINT

User Image bourbonboy32 Posted - 1 week ago

$BCDA how much cash on hand?

User Image nbstocks85 Posted - 1 week ago

$BCDA come to $ELWS about to breakout!!🚀🚀🚀🔥🔥🔥

User Image Sergioski Posted - 1 week ago

@Jesus2312 $BCDA is going to be an absolute monster when she takes off, Japan approval on the horizon and with three regenerative medicine candidates, two of which are in phase III trials with the FDA...BCDA-01 phase III part one shows statistically relevant data in patient subset with elevated NT-proBNP representing over 50% patients involved in the study if current Phase III part two which is designed to focus on this patient subset repeats the data already observed, then this will have FDA approval. Multi-Billion company that is unfairly beaten down by market makers and ready to soar, let's go!

User Image Jesus2312 Posted - 1 week ago

$KTRA yesterday was a good day for profits, now I'm loading $SINT and $BCDA

User Image digitalnuke Posted - 2 weeks ago

$BCDA Let's Go !!!

Analyst Ratings
HC Wainwright & Co. Buy Nov 14, 23
HC Wainwright & Co. Buy Oct 11, 23
HC Wainwright & Co. Buy Sep 6, 23
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy Jul 24, 23
HC Wainwright & Co. Buy Jun 21, 23
HC Wainwright & Co. Buy May 11, 23
HC Wainwright & Co. Buy Mar 30, 23
Dawson James Neutral Nov 11, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
FROST PHILLIP MD ET AL 10% Owner 10% Owner Jan 19 Sell 0.43 129,802 55,815 1,896,025 01/22/24
Altman Peter President and CEO President and CEO Jan 11 Buy 1.87 100 187 353,715 04/14/23
FROST PHILLIP MD ET AL 10% Owner 10% Owner Dec 16 Buy 1.68 595,238 1,000,000 2,025,827 12/20/22